Financial reports
10-Q
2023 Q3
Quarterly report
12 May 23
10-Q
2023 Q2
Quarterly report
7 Feb 23
10-Q
2023 Q1
Quarterly report
10 Nov 22
10-K
2022 FY
Annual report
28 Sep 22
10-Q
2022 Q3
Quarterly report
16 May 22
10-Q
2022 Q2
Quarterly report
11 Feb 22
10-Q
2022 Q1
Quarterly report
12 Nov 21
10-K
2021 FY
Annual report
28 Sep 21
10-Q
2021 Q3
Quarterly report
7 May 21
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Nov 22
8-K
Departure of Directors or Certain Officers
4 Nov 15
8-K
Sangui patent for Production of Artificial Oxygen Carriers granted
23 Oct 12
8-K
Sangui and SastoMed Complement Licensing Agreement in View of Increasing Sales Success
5 Sep 12
8-K
Sangui wound dressing patent granted
13 Apr 12
8-K
CE mark granted for wound spray based on Sangui patent
12 Apr 12
8-K
Entry into a Material Definitive Agreement
18 Feb 11
8-K
Changes in Registrant's Certifying Accountant
20 Dec 10
8-K/A
Changes in Registrant's Certifying Accountant
11 Sep 09
8-K
Changes in Registrant's Certifying Accountant
5 Aug 09
Registration and prospectus
424B3
Prospectus supplement
13 Feb 19
424B3
Prospectus supplement
13 Nov 18
424B3
Prospectus supplement
28 Sep 18
424B3
Prospectus supplement
3 May 18
424B3
Prospectus supplement
13 Feb 18
424B3
Prospectus supplement
21 Nov 17
424B3
Prospectus supplement
21 Nov 17
424B3
Prospectus supplement
18 Oct 17
424B3
Prospectus supplement
19 May 17
424B3
Prospectus supplement
22 Feb 17
Other
UPLOAD
Letter from SEC
7 Jun 21
UPLOAD
Letter from SEC
23 Apr 21
UPLOAD
Letter from SEC
1 Apr 21
EFFECT
Notice of effectiveness
7 Aug 15
CORRESP
Correspondence with SEC
6 Aug 15
UPLOAD
Letter from SEC
7 Jul 15
UPLOAD
Letter from SEC
23 Mar 15
UPLOAD
Letter from SEC
24 Feb 15
UPLOAD
Letter from SEC
12 Mar 12
CORRESP
Correspondence with SEC
1 Mar 12